Revlimid different doses
Active Awarded Last action
- Contract number
- 36C26026F0171
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $65,490
Award facts
- Contract value 100% obligated
- $65,490.12 Current and potential, with all options
- Completion date 71% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company has been awarded a delivery order valued at $65,490.12 for the supply of REVLIMID in different doses to Veterans Integrated Service Network 20 (VISN 20), with a performance location in Memphis, Tennessee. This is a firm fixed-price delivery order with an ultimate completion date of February 1, 2027, issued under Bristol-Myers Squibb's Federal Supply Schedule contract (ID: 36F79724D0101) for Pharmaceuticals and Drugs (FSS-61-IB) with the Department of Veterans Affairs. The award carries no set-aside designation, reflecting the contractor's status as a large biopharmaceutical manufacturer. The parent FSS contract, which carries a ceiling value of approximately $12.3 billion and extends through April 30, 2029, provides the Department of Veterans Affairs with access to negotiated pricing for a comprehensive range of pharmaceutical products across multiple therapeutic areas.
REVLIMID (lenalidomide) is a critical immunomodulatory agent used in the treatment of hematologic malignancies, including multiple myeloma and certain lymphomas, representing part of Bristol-Myers Squibb's specialized oncology portfolio that serves the VA healthcare system. Since 2022, the Department of Veterans Affairs has issued more than fifty delivery orders to Bristol-Myers Squibb under the FSS vehicle, with the majority supporting VISN 9, demonstrating sustained demand for the company's advanced cancer treatments and cell therapies that support the VA's mission to provide state-of-the-art oncology care to eligible veterans across the Veterans Health Administration network.
Quick answers
Who was awarded contract 36C26026F0171?
36C26026F0171 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 20 (Veterans Health Administration) on February 2, 2026.
How much is contract 36C26026F0171 worth?
The government has obligated $65,490 on 36C26026F0171.
Is contract 36C26026F0171 an order under another contract?
Yes. 36C26026F0171 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26026F0171 competed?
The extent of competition for 36C26026F0171 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award